[
  {
    "ts": "2025-03-18T19:00:00+00:00",
    "headline": "INCY Stock Down on Disappointing Skin Disease Study Data",
    "summary": "Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.",
    "url": "https://finance.yahoo.com/news/incy-stock-down-disappointing-skin-190000520.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "160ed3a2-08c8-3d57-b55f-9a377f5f6b78",
      "content": {
        "id": "160ed3a2-08c8-3d57-b55f-9a377f5f6b78",
        "contentType": "STORY",
        "title": "INCY Stock Down on Disappointing Skin Disease Study Data",
        "description": "",
        "summary": "Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.",
        "pubDate": "2025-03-18T19:00:00Z",
        "displayTime": "2025-03-18T19:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nURi29Wh6a5rz6SvQvvCDw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gUIojpJE4OxxDca8KkXZsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incy-stock-down-disappointing-skin-190000520.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incy-stock-down-disappointing-skin-190000520.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-18T12:05:00+00:00",
    "headline": "Stoke CEO exits; Medicare drug price talks advance",
    "summary": "Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.",
    "url": "https://www.biopharmadive.com/news/stoke-ceo-exits-medicare-drug-price-talks-advance/742780/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "f6daf487-54d3-3519-ab7c-7fea66fe9e33",
      "content": {
        "id": "f6daf487-54d3-3519-ab7c-7fea66fe9e33",
        "contentType": "STORY",
        "title": "Stoke CEO exits; Medicare drug price talks advance",
        "description": "",
        "summary": "Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.",
        "pubDate": "2025-03-18T12:05:00Z",
        "displayTime": "2025-03-18T12:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/stoke-ceo-exits-medicare-drug-price-talks-advance/742780/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stoke-ceo-exits-medicare-drug-120500604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STOK"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-18T09:32:57+00:00",
    "headline": "Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires",
    "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]",
    "url": "https://finance.yahoo.com/news/incyte-corporation-incy-among-best-093257980.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "00a394a3-e1a0-30b5-94bf-0589f0643fa6",
      "content": {
        "id": "00a394a3-e1a0-30b5-94bf-0589f0643fa6",
        "contentType": "STORY",
        "title": "Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires",
        "description": "",
        "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]",
        "pubDate": "2025-03-18T09:32:57Z",
        "displayTime": "2025-03-18T09:32:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Incyte Corporation (INCY) a Best Biotech Stock According to Billionaires?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F08AN_WgfDoxxGlrVQfGRQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ux9OKsmqTigW_m7aYltcpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-corporation-incy-among-best-093257980.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-corporation-incy-among-best-093257980.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]